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Background: Validation of biomarkers for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) across
data sets has proven disappointing. As immune signature may be affected by many factors, our objective was to
explore the shift in discriminatory cytokines across ME/CFS subjects separated by duration of illness.
Methods: Cytokine expression collected at rest across multiple studies for female ME/CFS subjects (i) 18 years or
younger, ill for 2 years or less (n = 18), (ii) 18–50 years of age, ill for 7 years (n = 22), and (iii) age 50 years or older (n = 28),
ill for 11 years on average. Control subjects were matched for age and body mass index (BMI). Data describing the levels
of 16 cytokines using a chemiluminescent assay was used to support the identification of separate linear classification
models for each subgroup. In order to isolate the effects of duration of illness alone, cytokines that changed significantly
with age in the healthy control subjects were excluded a priori.
Results: Optimal selection of cytokines in each group resulted in subsets of IL-1α, 6, 8, 15 and TNFα. Common to any 2
of 3 groups were IL-1α, 6 and 8. Setting these 3 markers as a triple screen and adjusting their contribution according to
illness duration sub-groups produced ME/CFS classification accuracies of 75–88 %. The contribution of IL-1α, higher in
recently ill adolescent ME/CFS subjects was progressively less important with duration. While high levels of IL-8 screened
positive for ME/CFS in the recently afflicted, the opposite was true for subjects ill for more than 2 years. Similarly, while
low levels of IL-6 suggested early ME/CFS, the reverse was true in subjects over 18 years of age ill for more than 2 years.
Conclusions: These preliminary results suggest that IL-1α, 6 and 8 adjusted for illness duration may serve as robust
biomarkers, independent of age, in screening for ME/CFS.
Keywords: Cytokines, Chronic fatigue, Menopause and immunity, Immune signaling, Classification modelBackground
Myalgic encephalomyelitis/chronic fatigue syndrome
(ME/CFS) is a complex and poorly understood illness
[1] that affects up to 4 million individuals [2, 3] and
costs an estimated $35 billion per year in lost productiv-
ity and health care [4, 5] in the US alone. It presents in a
significant fraction of cases as a sequelum of acute infec-
tion [6, 7] and while men are susceptible, ME/CFS af-
fects a disproportionate number of women [8] in a ratio
of up to 6:1 [9]. Moreover recent preliminary work by* Correspondence: gbroderick@nova.edu
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(http://creativecommons.org/publicdomain/zeour group suggests that this illness may present different
patterns of cytokine expression in women as it does in
men [10]. Biomarkers for ME/CFS have been reported
[11] but validation in external datasets has proven diffi-
cult [12, 13] at least in part because of the heteroge-
neous composition of subject cohorts, in particular with
regard to sex and age and the confounded effects
thereof. Indeed in recent work, Lewis et al. [14] con-
clude that older ME/CFS patients (age >50 years) dem-
onstrate a disease phenotype very different from that of
younger patients (16–29 years) who may be more likely
to develop CFS following an infection, including greater
autonomic dysfunction and depressive symptoms. In
addition Hornig et al. [15] demonstrated cytokine profil-
ing differences between short and long duration ofis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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healthy controls. Menopausal status also emerged a seg-
regating feature in differentiating sub-classes of ME/CFS
in work by Vollmer-Conna et al. [16].
Influences of sex on immune function have long been
recognized. The higher risk of women developing auto-
immune diseases suggests that the latter may be medi-
ated by sex steroids [17]. Accordingly, both cellular and
humoral immune responses may be modulated during
the different phases of the menstrual cycle with NK cell
cytolytic activity decreasing in the pre-ovulatory period
[18, 19] and a shift towards Th-2 immunity occurring in
the luteal phase [20]. Our work has shown that de-
creased NK cell cytotoxic function is a consistent feature
in a group of older ME/CFS subjects [21]. In addition,
Cannon et al. [22] reported that while neutrophil count
normally increased from the follicular to luteal phase in
healthy women, it persisted at luteal levels in ME/CFS.
Other immunological features have also been reported.
For example, postmenopausal women typically show a re-
duction in total lymphocyte count with this decrease in-
volving mainly B and CD4+ T lymphocyte subpopulations
[23]. These same authors report that women with prema-
ture menopause had lower CD4+, higher CD8+ and
higher NK cell counts than fertile women of the same age.
More recent work has confirmed that estrogen alters
levels of cortisol, the major mediator of the HPA axis and
immune responses, during menstrual cycles and in post-
menopausal women [24, 25]. These observations argue in
favor of a stratification of subjects on the basis of meno-
pausal status when studying illnesses affecting immune
and endocrine function. In addition there are changes in
the risk for autoimmune and chronic inflammatory dis-
eases between both pre and post-menopausal women
compared to men [26]. Aging is another factor to take into
account as it is associated with an increased prevalence of
chronic inflammatory diseases and immune dysregulation
[27, 28]. Progression of illness-specific changes in immune
function are therefore confounded with changes expected
as a result of normal ageing and menopause. In this study
we attempted to identify shifts in the expression of 16 cy-
tokines that might be primarily driven by illness while
controlling for those that are associated with normal im-
mune ageing and menopause. In an overall group of n =
68 female ME/CFS subjects and n = 73 healthy control
subjects, ranging in age from 12 to 75 years, we found that
the expression of IL-1α, 6, and 8 in blood supported a
classification accuracy of 75–88 % for ME/CFS when ad-
justed for duration of illness.
Methods
Subject cohorts
The cohort of young subjects <18 years of age is de-
scribed in previously [7]. In brief, this cohort consistedof n = 12 adolescent subjects with post-infectious ME/
CFS resulting from infectious mononucleosis (IM)
(mean age 16 years, mean BMI 24) and case matched re-
covered control subjects (mean age 16 years, mean BMI
23) recruited and assessed as part of a 2-year prospective
study 301 adolescents recruited from the greater
Chicago area. Adolescents were identified via school
nurses (middle school, high school and college/university),
pediatric practices, including the Pediatric Practice Re-
search Group and the Virology Laboratory of Children’s
Memorial Hospital (now the Ann & Robert H Lurie
Children’s Hospital of Chicago). Clinical evaluation in-
cluded laboratory tests to rule out medical causes of ME/
CFS (e.g., chemistry panel, complete blood count, erythro-
cyte sedimentation rate, liver chemistries, urine toxicol-
ogy, urinalysis and thyroid function tests). The examining
physician made a diagnosis of ME/CFS, ME/CFS-ex-
plained, or recovered on each subject. These diagnoses
were then blindly reviewed by an expert panel using the
Jason revision for pediatrics [29] of the Fukuda criteria [1].
Each subject also completed the Chalder Fatigue Scale at
6, 12 and 24 months [30], along with the Youth Medical
Questionnaire, Modifiable Activity Questionnaire, Sleep
Assessment Questionnaire, and the Structured Clinical
Interview for the DSM-IV Child Version, Child/Young
Adult Behavior Checklist, Child/Young Adult Self-Report,
and Life Events and Difficulty Questionnaire [31]. At 24-
months post-IM onset, 13 subjects satisfied the criteria for
ME/CFS, all of whom were young women. Plasma sam-
ples were available for n = 1 and n = 9 of these 13 ME/CFS
patients at 12 and 24-months after diagnosis with IM re-
spectively. These were case matched with samples at
24 months from n = 12 recovered controls based on age
(+/− 1 year) and Tanner stage (4 or 5).
The second cohort consisted of adult female ME/CFS
patients (n = 40; mean age 50, mean BMI 27) that were
recruited from the ME/CFS and Related Disorders Clinic
at the University of Miami. A diagnosis of ME/CFS was
made using the International Case Definition [1, 31].
Healthy female controls (n = 59; mean age 53, mean
BMI 26) were recruited from the same metropolitan area
under a NIH funded study. This cohort was enriched by
integrating a third smaller subject group consisting of
n = 10 female ME/CFS subjects (mean age 43 years,
mean BMI 27) and 10 female healthy control (HC) sub-
jects (mean age 45 years, mean BMI 32) recruited as part
of a separate ongoing study and assessed according to the
same protocols and case definition criteria.
This overall set of female ME/CFS subjects recruited
across the 3 studies was combined and then separated
into 3 groups according to age and illness duration as
follows: (i) adolescent early course subjects, 18 years or
younger, ill for 2 years or less (n = 18), (ii) adult pre-
menopausal mid-course subjects, 18–50 years of age, ill
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menopausal late course subjects, age 50 years or older
(n = 28), ill for 11 years on average. Control subjects
were matched for age and body mass index (BMI).
All ME/CFS study subjects had a SF-36 summary
physical score (PCS) below the 50th percentile, reflecting
a level of impairment exceeding the population norm.
Exclusion criteria for ME/CFS included all of those listed
in the current Centers for Disease Control (CDC) ME/
CFS case definition, including the listed psychiatric ex-
clusions, as clarified in the International CFS Working
Group [32]. All ME/CFS subjects were assessed for psy-
chiatric diagnosis at the time of recruitment with the
Composite International Diagnostic Instrument [29].
Based on this assessment, we excluded subjects with
DSM IV diagnoses for psychotic or melancholic depres-
sion, panic attacks, substance dependency, or psychoses
as well as any subjects currently suicidal. We also ex-
cluded subjects with Borderline or Antisocial Personality
Disorder. Subjects had no history of heart disease,
COPD, malignancy, or other systemic disorders that
would be exclusionary, as clarified by Reeves et al. [32].
Ethics statement
Informed consent to participate in the study was obtained
for all studies, including the Chicago-based prospective
study, from all participants (or their parent or guardian in
the case of children under 16). Consent and study proto-
cols were approved as appropriate by the Institutional
Review Board of the Department of Veterans Affairs
Medical Research Development Committee (protocol
#4987.76) and the Children’s Memorial Hospital (now
Ann & Robert H Lurie Children’s Hospital of Chicago)
(IRB#2009-13726). Ethics review and approval for data
analysis was also obtained by the IRB of the University of
Alberta Health Research Ethics Board-Biomedical Panel
(protocols Pro00018859 and Pro00004286).
Cytokine profiles
In all cohorts morning fasting AM blood samples were
collected into ethylene diamine tetra acetic acid (EDTA)
anticoagulant tubes. Plasma was separated within 2 h of
collection and stored at −80 °C until assayed. We mea-
sured 16 cytokines in plasma using Quansys reagents
and instrument (Quansys Biosciences, Logan, Utah).
These were interleukin (IL) 1α, 1β, 2, 4, 5, 6, 8, 10,
12p70, 13, 15, 17 and 23 as well as interferon gamma
(IFNγ), tumour necrosis factor alpha (TNF α) and
lymphotoxin-α (LTα) The Quansys Imager, driven by an
8.4 megapixel Canon 20D digital SLR camera, supports
96 well plate based chemiluminescent imaging. The Q-
Plex™ Human Cytokine-Screen (16-plex) is a quantitative
enzyme-linked immunoabsorbent assay (ELISA)-based
test where sixteen distinct capture antibodies have beenabsorbed to each well of a 96-well plate in a defined
array. The range of the cytokine concentrations used in
the standard calibration samples were adjusted for each
cytokine along with sample exposure time to provide the
most reliable comparison possible between ME/CFS pa-
tients and controls across the range of cytokine concen-
trations known and expected in plasma. For the
standard curves, we used the second order (k = 2) poly-
nomial regression model (parabolic curve): Yp = b0 +
b1X
1.... + bkX
k, where Yp is the predicted outcome value
for the polynomial model with regression coefficients b1
to bk for each degree and y intercept b0. Details of the
protocol and assay variability have been reported previ-
ously by our group [33–35]. In brief, replicate error in
the measurement of IL-1α, IL-10 and IL-17 using this
panel does not readily support subject-to-subject com-
parisons however the resolution is more than adequate
for use in comparisons across patient groups as a whole.
Values below detection limit were replaced with the low-
est concentration recorded for each specific cytokine
within each subject group (see Supplemental Table S3 in
[34]). Statistics describing the distribution of values ob-
tained in each subject subgroup are shown in Additional
file 1: Table S1(a) and (b). To verify consistency in the
collection and handling of blood samples across the Chi-
cago and Miami clinical sites we performed a principal
component analysis (PCA) [36] capturing co-expression
patterns of the 16 cytokines in healthy control subjects.
Additional file 2: Figure S1 shows the Hotelling T2 stat-
istic [37], a measure of departure from the co-expression
model, for each of the samples collected in Chicago from
the adolescent control subjects and those collected in
Miami from the two groups of adult subjects. Results
confirmed that the middle-aged and adolescent groups
were statistically comparable in broad co-expression des-
pite samples being collected at two separate sites. In
addition the deviation cytokine co-expression in the
healthy subjects aged 50 years and older aligns with ob-
servations of immune shift in healthy women of post-
menopausal age.
The full set of de-identified, coded and normalized
data used in this work is available in Additional file 3:
Table S6. This same file contains symptom severity
scores based on the Multidimensional Fatigue Inventory
(MFI) [38] for all ME/CFS subjects older than 18 years
of age (Additional file 3: Table S7). Symptom severity in
the adolescent cohort (age ≤18 years) was assessed using
the Chalder Fatigue Scale [30] and is described separ-
ately in Katz et al. [7].
Statistical analysis
All cytokine concentrations were log base 2 transformed
(log2), then centered and range adjusted by way of s stand-
ard z-score normalization. In assessing the significance of
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variance (ANOVA) was applied as was the non-parametric
Kruskall-Wallis test. Null hypothesis p-values obtained
through these tests were used as criteria for selecting
those cytokines that did not vary significantly between age
groups in the healthy control subjects only. The signifi-
cance of pair-wise differences in concentration across any
two groups was estimated using a standard parametric
two-tailed t-test in conjunction with the non-parametric
Wilcoxon ranksum test.
Linear discriminant classification models were gener-
ated that assigned subjects to ME/CFS or control groups
based on expression of a subset of the 16 cytokines mea-
sured. Selection of specific cytokines for inclusion into
the model was conducted using a step-wise selection
procedure whereby candidates are individually added
and removed from the discriminant function based on
their partial F statistic [39]. According to this model an
observed row x from the sample array is classified into
group I rather than group J if 0 < B0 + x*B, where the co-
efficient vector B and intercept vector B0 are estimated
from the data. Classifier performance was assessed in
terms of overall accuracy (correct rate), sensitivity,
specificity, positive predictive value (PPV), and negative
predictive value (NPV). The evolution of linear discrim-
inant coefficients with duration of illness was expressed
as a second order polynomial regression model (para-
bolic curve): Yp = b0 + b1X.... + bk X
2, where Yp is the pre-
dicted outcome value for the polynomial model with
regression coefficients b1 to bk for each degree and inter-
cept b0. These calculations were performed using the
classify and classperf functions available in the MatLab
Statistics Toolbox and the MatLab Bioinformatics Tool-
box (The MathWorks, Inc., Natick, MA).
Correlation of MFI symptom severity with cytokine
expression reported in Additional file 1: Table S4, was
based on the partial Spearman rank correlation cor-
rected for BMI and duration of illness. This measure
and its application are described further in Emmert-
Streib [40] as well as Magwene and Kim [41]. Partial
correlation was calculated using the partialcorr function
available in the MatLab Statistics Toolbox (The
MathWorks, Inc., Natick, MA).
Results
Differences in cytokine expression between healthy and
ME/CFS populations
Differences in the expression of individual markers be-
tween HC subjects and subjects diagnosed with ME/
CFS) were assessed in each of the age and duration of
illness group using the non-parametric ranksum test and
the standard two-tailed t test applied to the log2-
transformed cytokine data (Additional file 1: Table S2).
Significant differences in both the mean (t test) andmedian log-transformed expression values (ranksum
test) were observed between the HC and ME/CFS (p <
0.05) in at least one of the 3 subgroups for 7 out of the
16 cytokines measured. These differences were especially
abundant in the sub-group of subjects aged 50 years or
more and ill for 11 years on average. In the latter, IL-4,
IL-5, IL-12 and LTα were increased in expression in
ME/CFS, while IL-8 and IL-15 were expressed at lower
levels in ME/CFS. Conversely increased expression
values for IL-8 were observed in adolescent ME/CFS
subjects with log-transformed concentrations of IL-23
being expressed at significantly lower levels in this sub-
group.
Validating a prior classification model
As cytokines are not expressed independently of one an-
other [34], we had previously applied both a sequential
step-wise selection procedure and an all-possible subsets
procedure to identify subsets of cytokines that when
used as the basis of a linear classification model might
provide a co-expression signature characteristic of ME/
CFS in the adolescent cohort used here [35]. Use of the
sequential selection procedure identified IL-1a, IL-6, IL-
8, IL-13 and IL-23 as potential markers of ME/CFS in
this adolescent population (Table 1). Of these cytokines,
IL-6, IL-8 and IL-23 were also selected by the all-
possible subsets method forming the basis for a reduced
consensus model. As described in Broderick et al. [35]
random sub-sampling of the adolescent subjects indi-
cated that IL-6 and 8 provided an especially robust basis
for a minimal classification model of post-infectious
ME/CFS in our adolescent population. Even this min-
imal model of ME/CFS supported a classification accur-
acy of close to 80 % in the adolescent training set.
However as shown in Table 1, all three variants of this
classification model extrapolated poorly to the older
mid-course and late course subject sub-groups with ac-
curacies of less than 50 %.
Selecting cytokines broadly conserved across age and
BMI
Even in healthy individuals cytokine expression is
influenced by a variety of factors such as age and BMI
[17, 42–44]. Indeed when examining changes in cytokine
expression in healthy individuals alone we found that
the majority of the 16 cytokines measured here changed
significantly in expression (Table 2a). Despite trans-
formations to the data, significance analysis based on
classical ANOVA was further verified using the Kruskall-
Wallis non-parametric test and variable selection was
based on the more conservative result. Only IL-6, TNF-α
and LTα levels were not significantly different among
healthy control subjects across all 3 age subgroups
(Table 2a). Expression of IL-1α, 8 and 15 was statistically
Table 1 Extrapolation of classification models identified in adolescent CFS (Broderick et al., 2012) to adult pre and post-menopausal
groups
Classification based on Stepwise model of IL-1α, 6,8,13,23 Consensus model of IL-6, 8, and 23 Minimal model of IL-6 and 8
(a) Training set: Age < =18 years
Correct rate 0.93 0.86 0.79
Error rate 0.07 0.14 0.21
Sensitivity 0.94 0.89 0.78
Specificity 0.92 0.83 0.79
Positive predictive value 0.89 0.80 0.74
Negative predictive value 0.96 0.91 0.83
(b) Test set: 18 < Age < = 50 years
Correct rate 0.49 0.26 0.35
Error rate 0.51 0.74 0.65
Sensitivity 0.09 0.23 0.09
Specificity 0.90 0.29 0.62
Positive predictive value 0.50 0.25 0.20
Negative predictive value 0.49 0.26 0.39
(c) Test set: Age > 50 years a
Correct rate 0.46 0.29 0.39
Error rate 0.54 0.71 0.61
Sensitivity 0.00 0.32 0.14
Specificity 0.93 0.25 0.64
Positive predictive value 0.00 0.30 0.29
Negative predictive value 0.48 0.27 0.43
an = 28 of 47 HC to match ME/CFS age and BMI
Table 2 Results of one-way ANOVA and Kruskal–Wallis tests in healthy control (HC) subjects only (a) across all 3 age groups, and (b)
across the 2 age groups with predominantly premenopausal subjects (age ≤50 years)
(a) HC all age groups (b) HC groups age ≤50 years only
p ANOVA p Kruskalwallis p ANOVA p Kruskalwallis
BMI 0.00 0.01 0.00 0.00
IL-1α 0.23 0.04 0.12 0.12
IL-1β 0.00 0.00 0.00 0.00
IL-2 0.27 0.01 0.32 0.02
IL-4 0.00 0.00 0.18 0.01
IL-5 0.00 0.00 0.00 0.00
IL-6 0.99 0.89 0.91 0.95
IL-8 0.08 0.01 0.27 0.06
IL-10 0.00 0.00 0.00 0.00
IL-12p70 0.00 0.00 0.02 0.01
IL-13 0.00 0.00 0.00 0.00
IL-15 0.22 0.04 0.98 0.41
IL-17 0.00 0.00 0.00 0.01
IL-23 0.00 0.00 0.00 0.00
IFNγ 0.02 0.02 0.00 0.01
TNFα 0.89 0.33 0.82 0.17
LTα 0.11 0.75 0.09 0.67
p = > 0.10
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premenopausal healthy individuals (Table 2b). While sig-
nificant differences in BMI were seen in healthy subjects
between the adolescent subgroup and the subgroups with
older subjects, the overall range of values was such that
the vast majority of subjects were non-obese (58 of 73
with BMI <30 kg/m2) [45].
In an attempt to remove the confounding effects of
age and BMI on cytokine expression, we constructed a
new set of classification models using only IL-1a, IL-6,
IL-8, IL-15, TNF-α and LTα as candidate markers since
these were reasonably invariant in healthy subjects. Cy-
tokines IL-1α, TNF-α and LTα, IL-6 and IL-8 had been
previously selected as discriminatory markers [35] in the
adolescent set and were retained here as the basic model
(Table 3) producing a classification accuracy of 88 % in
this subgroup. Repeating the stepwise selection proced-
ure for the middle aged mid-course subgroup led to the
identification of IL-1α and IL-15 as being the best
markers for this subgroup yielding an accuracy of 72 %.
Likewise in the predominantly post-menopausal late-
course group, IL-6, IL-8, IL-15 and TNF-α were selected
to deliver a classification accuracy of 84 %. As theseTable 3 Best Stepwise models selected for each set from cytokines
Subject sub-group Classification model
Training selection





Positive predictive value 0.84
Negative predictive value 0.91
Training selection





Positive predictive value 0.73
Negative predictive value 0.71





Positive predictive value 0.83
Negative predictive value 0.85
an = 28 of 47 HC to match CFS/ME age and BMIsubgroup specific marker sets overlap, the applicability of
the simple model identified in the adolescent subgroup
was tested on both other age and illness duration groups
yielding accuracies of 37 and 48 %. To explore whether
this decrease in performance was related to the choice of
cytokines, we constrained the structure of the classifica-
tion model to be based on IL-1α, IL-6 and IL-8 but
allowed the coefficients to be tuned for each of the illness
subgroups. When coefficients were tuned in this way the
classification accuracy based on IL-1α, IL-6 and IL-8 rose
to 77 and 75 % in the middle-aged and post-menopausal
subgroups respectively (Table 3). As IL-1α, IL-6 and IL-8
were selected from a candidate set of cytokines that were
reasonably invariant across age and BMI in healthy sub-
jects this result suggests that duration of illness may be a
main factor driving the need for parameter tuning across
ME/CFS subgroups, at least in the group of cytokines
measured here. This choice of markers would also be con-
sistent with a cursory analysis of illness severity showing
that IL-1α and IL-8 in particular display a correlation of at
least marginal significance (p ≤ 0.07) or better with the
general fatigue, physical fatigue and reduced activity com-
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The classification results above suggest that IL-1α, IL-6
and IL-8 may be broadly applicable as ME/CFS illness
markers but that their contribution should be adjusted
based on duration of illness and perhaps other related
covariate factors. To assess the variability of such adjust-
ments the coefficients for these cytokines in the linear
classification model were estimated repeatedly on 50
random subsets of 10 healthy control and 10 ME/CFS
subjects in each illness duration subgroup. Subjects
would be assigned to the ME/CFS class if 0 < α0 + α1×
[IL-1a] + α2 × [IL-6] + α3 × [IL-8], where [x] is the z score
normalized concentration of cytokine x based on the
mean and standard deviation values listed in Additional
file 1: Table S3. Results of this piece-wise optimal tuning
of classification coefficients are shown in Table 4 sup-
porting an accuracy in classification of approximately
75 ± 8 % standard error on these smaller random sub-
sets. Sensitivity values were 75 ± 12 % to 78 ± 9 % in the
adult subsets. Corresponding specificity levels exceeding
73 ± 11 % ranging up to 83 ± 8 %.
The corresponding mean and median values for these
optimally tuned coefficients are listed in Table 5 and
shown in Fig. 1. These indicate that duration of illness
influences both the magnitude and the polarity of the
contribution made by each cytokine in determiningTable 4 Performance statistics for classification models built
from 50 random subsets of 10 healthy and 10 CFS/ME subjects
Classification based on IL-1α, 6 and 8 Median (MADM
Std Err a)
Mean (Std Err)
(a) 50 random subsets: Age < =18 years
Correct rate 0.90 (0.01) 0.89 (0.06)
Sensitivity 0.90 (0.00) 0.92 (0.06)
Specificity 0.85 (0.01) 0.86 (0.08)
Positive predictive value 0.87 (0.01) 0.87 (0.07)
Negative predictive value 0.90 (0.00) 0.92 (0.06)
(b) 50 random subsets: 18 < Age < = 50 years
Correct rate 0.75 (0.01) 0.76 (0.08)
Sensitivity 0.80 (0.02) 0.78 (0.09)
Specificity 0.70 (0.02) 0.73 (0.11)
Positive predictive value 0.73 (0.01) 0.75 (0.10)
Negative predictive value 0.78 (0.01) 0.77 (0.08)
(c) 50 random subsets: Age > 50 years b
Correct rate 0.80 (0.01) 0.79 (0.08)
Sensitivity 0.80 (0.02) 0.75 (0.12)
Specificity 0.80 (0.01) 0.83 (0.08)
Positive predictive value 0.80 (0.01) 0.82 (0.08)
Negative predictive value 0.80 (0.02) 0.77 (0.09)
aMADM Std Err = 1.4826 ×MADM/√n
bn = 28 of 47 HC to match ME/CFS age and BMImembership to the ME/CFS class. The coefficient α1 for
IL-1α suggests that increased levels of the latter are most
characteristic of ME/CFS in the early course of illness
but that this feature decreases in importance as illness
progresses. Coefficients α2 and α3 actually reverse in po-
larity as illness progresses with a combination of lower
than average IL-6 and higher than average IL-8 levels
being more discriminatory for early stage ME/CFS but
the reverse pattern being more prominent in subjects
with more established illness. Changes in the inter-
cept α0 and the coefficients α1, α2, α3 with respect to
duration of illness were captured using a simple sec-
ond order polynomial of the form αi = β0 + β1 × (years
ill) + β2 × (years ill)
2. This regression model is pre-
sented in Table 6. Results show that in the case of all
classification coefficients, the duration of illness is a
highly significant contributor (F > 32; p < 0.01). Indeed
close to 60 % of the total variability in the classifica-
tion coefficients for IL-6 and IL-8 are captured by
duration of illness alone (R2 = 0.57). However only
slightly more that 30 % of the total variability in the
classification coefficients for IL-1α as well as that for
the intercept are supported by changes in duration of
illness. To evaluate the impact of this unexplained
variability on classification accuracy we applied the
simple protocol proposed in Additional file 4: Figure S2
where duration of illness alone is first used to calculate
the appropriate values of the classification weights αi for
IL-1α, IL-6 and IL-8 using the βi values listed in Table 6.
Using the resulting estimates of coefficients α0, α1, α2, α3
in the linear classification model each subject was assigned
a predicted ME/CFS (score >0) or non-ME/CFS status
(score ≤0). The protocol based on duration of illness alone
supported a classification accuracy of 63 % across the full
range of illness duration, a performance comparable to
that obtained with an optimal tuning based on all subjects
(Additional file 1: Table S5). However important gaps in
performance emerged across the different phases of ill-
ness. This was especially obvious for classification per-
formed in the mid-range of illness duration (i.e. 6–7 years
ill). These results illustrate that although duration of ill-
ness may be a highly significant contributor to the evolu-
tion of the classification coefficients (p < 0.01), other
covariate factors related to illness progression may also
play an important role, in particular during the transition
from early to late phase.
Discussion
There is mounting evidence suggesting that ME/CFS
may be characterized by a significant imbalance in im-
mune and endocrine function and that this imbalance
may be perpetuated by an altered homeostatic response.
Cytokine profiles that are characteristic of this persistent
imbalance in immune regulation function have been
Table 5 Distribution statistics for coefficients in linear discriminant model based on 50 random subsets of 10 healthy and 10 CFS/ME
subjects in each age group
(a) Median (MADM-based Std Err a) Age < =18 years 18 < Age < = 50 years Age > 50 years
Discriminant coefficients (n = 50)
IL-1α α1 1.93 (0.11) 0.51 (0.06) 0.14 (0.10)
IL-6 α2 −2.08 (0.17) 0.91 (0.12) 1.28 (0.07)
IL-8 α3 2.89 (0.18) −0.60 (0.06) −1.36 (0.12)
Constant term α0 −1.86 (0.09) −0.39 (0.05) −0.49 (0.05)
Duration of illness (years) 2.00 (0.00) 6.50 (1.74) 8.50 (1.26)
(b) Mean (Std Err)
Discriminant coefficients (n = 50)
IL-1α α1 2.41 (0.23) 0.53 (0.10) 0.14 (0.13)
IL-6 α2 −2.36 (0.19) 1.09 (0.13) 1.51 (0.13)
IL-8 α3 3.53 (0.27) −0.92 (0.14) −1.52 (0.19)
Constant term α0 −2.07 (0.15) −0.48 (0.06) −0.61 (0.09)
Duration of illness (years) 2.00 (0.00) 7.09 (1.28) 10.64 (1.46)
aMADM Std Err = 1.4826 ×MADM/√n
Russell et al. BMC Immunology  (2016) 17:3 Page 8 of 11reported previously by our group as well as by others de-
scribed [10, 15, 34, 35]. Broad use of cytokine expression
patterns as markers of illness is not without its chal-
lenges as these can be difficult to measure and are
affected by a variety of factors even in a healthy popula-
tion such as age, sex, BMI, etc.… Indeed Craddock et al.
[46] demonstrated mathematically that basic differences
in immune and endocrine regulatory wiring in men ver-
sus women is such that chronic response to insult in
each sex can be significantly different. The concurrent
measurement of multiple cytokines can serve to provideFig. 1 Relative contribution to classification of ME/CFS subjects
versus healthy control subjects across duration of illness for
cytokines largely unaffected by age and BMI. Average value with
standard error for the coefficients of IL-1α, IL-6 and IL-8 in a linear
model for classification of ME/CFS subjects as estimated across 50
random subsets of n = 10 ME/CFS and n = 10 healthy control
subjects sampled from subgroups of differing illness durationa measure of internal validation however the changes oc-
curring as a result of illness progression as well as the
shift that normally occurs in a healthy control popula-
tion must also be considered. This study is a continued
exploration of how characteristic cytokine expression
might be in ME/CFS and how such a signature could be
used to reliably isolate ME/CFS subjects from their
healthy counterparts regardless of age and duration of
illness. The cytokine-based classification model initially
reported in Broderick et al. [35], showed promise when
applied to the adolescent ME/CFS cohort reinforcing the
notion that cytokine profiling may be a useful tool in
supporting a diagnosis of ME/CFS. However this early
model did not extrapolate well to a larger cohort of adult
ME/CFS subjects. In any classification system it is im-
portant that we control for factors affecting the expres-
sion of those same candidate markers in healthy
individuals. In this work we attempted to normalize and
remove changes in immune signaling that are driven by
age [17, 42, 43] and BMI [44] in a healthy population.
As a significant segment of the healthy subjects used
here as a comparator group straddled the average age of
menopause we reasoned that this may be one of the fac-
tors affecting the stability of biomarker discovery in the
broader ME/CFS population. In a recent review by
Gamiero, Romão and Castelo-Branco [43] evidence sug-
gests that healthy post-menopausal women exhibit ele-
vated levels of IL-6 and IL-18 accompanied by decreased
levels of TNF-α and LTα compared to their middle-aged
pre-menopausal counterparts. While the mean levels of
TNF-α and LTα exhibited a decreasing trend in healthy
women over 50 years of age, these trends did not achieve
statistical significance in this work. Levels of IL-18 were
not measured in the current study but levels of IL-6
Table 6 Regression models for discriminant coefficients as a function of duration of illness
Regression Model Intercept β0 β1 (years ill) β2 (years ill
2) R2 F p
IL-1a coefficient α1 3.42 (2.80, 4.04) −0.75 (−0.97, −0.52) 0.04 (0.02, 0.06) 0.347 38.980 0.000
IL-6 coefficient α2 −4.11 (−4.80, −3.43) 1.31 (1.06, 1.56) −0.07 (−0.09, −0.05) 0.573 98.510 0.000
IL-8 coefficient α3 5.84 (4.95, 6.73) −1.71 (−2.04, −1.38) 0.09 (0.07, 0.12) 0.573 98.504 0.000
Constant term α0 −2.56 (−3.00, −2.12) 0.45 (0.29, 0.62) −0.02 (−0.04, −0.01) 0.310 32.986 0.000
() indicates the 95 % confidence interval
R2 is Pearson correlation coefficient and p is the null probability of the F statistic
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subjects studied here. It is important to note that contrary
to the studies reviewed in Gamiero, Romão and Castelo-
Branco [43] the subgroups used here were based solely on
age and that the expression levels of sex hormones were
unavailable to confirm menopausal status. Nonetheless we
found significantly higher IL-6 expression in the older
ME/CFS subgroup compared to the middle-aged ME/CFS
group. Though these changes could not be associated dir-
ectly with menopausal status here, this observation none-
theless aligns with recent work by Boneva et al. [47] where
ME/CFS was associated with early hysterectomy and/or
menopause, linking this condition to the reduction or de-
pletion of endogenous female sex hormones and to the
possibility that menopause-like changes in immune signa-
ture may constitute an inherent component of ME/CFS
pathology. Such a link has been observed in other com-
plex illnesses with immune involvement [48].
After controlling for age and BMI, we found that it
might be possible to support the diagnosis of ME/CFS in
a broad population by adjusting the relative importance
of IL-1α, IL-6 and IL-8 expression to the duration of ill-
ness. In a recent study, Hornig et al. [15] compared
plasma cytokine profiles in ME/CFS subjects ill for
1.7 years on average (std.dev. 0.8) (mean age 40.5 years;
std. dev. 13.6 years) with those ill for 15.6 years on aver-
age (std. dev. 8.2) (mean age 50.2 years; std. dev. 11.4) as
well as with age-matched control subjects. As in the
current work, the latter found a decrease in IL-1α and
IL-8 in the ME/CFS cohort with longer duration illness
compared to the group with a more recent onset (p <
0.01, <0.0001 respectively). These investigators also re-
ported significantly depressed IL-6 concentrations in
subjects with more established illness (p < 0.05). A simi-
lar decrease was also observed here when comparing IL-
6 levels in the late stage ME/CFS subgroup (ill for
11 years on average) with the early stage subgroup ill for
2 years or less. However we also found that this decrease
in IL-6 expression was even more pronounced in the
mid-course subgroup (average illness duration of 7 years)
and that levels increased again in the late course but
remained below those expressed in the early stage. In
comparing these works further it is important to recall
that Hornig et al. [15] used a arbitrary threshold of3 years to define long versus short illness duration and
that subject groups spanned across the average age of
menopausal onset (approx. 50 years) [49, 50]. Despite
these differences in granularity and subgroup definition
the subjects we studied in this work appear to display
cytokine profiles similar to those found in the larger
ME/CFS population studied by Hornig et al., [15].
Extending beyond group-wise comparisons, our study
attempts to identify a subset of cytokines that when used
together might provide a highly discriminatory signature
for ME/CFS that is robust to differences in age, BMI and
could be adjusted for duration of illness. The panel pro-
posed here based on the co-expression of IL-1α, IL-6
and IL-8 supports an optimal accuracy of 78–88 % in a
random internal cross-validation. More importantly the
relative contribution of each of these cytokines seems to
shift with duration of illness. A co-expression pattern of
increased IL-1α and IL-8 in the context of decreased IL-
6 emerged as characteristic of early course illness com-
pared to age and BMI-matched control subjects. In
contrast elevated IL-1α, and IL-6 co-expressed in the
context of lower than average IL-8 was a more abundant
pattern in mid and late course ME/CFS subjects com-
pared to age and BMI-matched controls. Once again im-
portant to note that Hornig et al. [15] focused on features
that discriminate ME/CFS subjects with early-stage illness
from those with established illness. In this work we focus
on features that distinguish ME/CFS from age and BMI-
matched healthy control subjects, examining instead how
these might change at different stages of illness.
This remains an exploratory first analysis of how a set of
blood-borne immune markers might be used to support
the accurately diagnosis ME/CFS in an efficient and effect-
ive way. Several challenges persist in moving to larger
multi-site validation studies. For example even though all
assays were performed by the same diagnostic laboratory
(Miami) and collected using the same prescribed protocol,
the phlebotomy teams were specific to each site and fu-
ture studies should strive to better capture such potential
sources of bias. Nonetheless the current work describes a
protocol that could be useful in assessing a much broader
variety of potential markers such as neuropeptide Y
(NPY), previously shown by our group to be a correlate of
ME/CFS severity [51]. Extending the marker set to include
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would also be useful. Studies of cerebral spinal fluid (CSF)
from ME/CFS subjects have pointed to a characteristic
decrease in IL-10 levels confirming illness effects reach-
ing beyond the peripheral circulation to the central
nervous system [52]. While the panel based on IL-1α,
IL-6 and IL-8 levels in peripheral blood described here
shows initial promise it remains paramount to further
validate in a larger and even more varied cohort to
ensure a robustness that would be compatible with clin-
ical use. In keeping with this, it is important that these
biomarkers remain reliable in the context of the often
complex and broad set of co-morbid conditions afflicting
ME/CFS sufferers.
Conclusions
While the markers proposed here show promise, the
present study highlights how progression of the illness
itself may obscure the validation of potentially useful
markers and proposes a regression approach that might
be used to address this challenge. Though direct transla-
tion into clinical use may be premature at this time, we
believe that insights such as these are important to further
understanding the shifting immune biology of ME/CFS.
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